Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9194748 | 1.00 | ABCC9 (0.43) | ABCC9KDM4E | |
| SCHEMBL9194740 | 1.00 | ABCC9 (0.43) | ABCC9KDM4E | |
| SCHEMBL7048894 | 1.00 | ABCC9 (0.43) | ABCC9KDM4E | |
| Hydrochloric Acid SCHEMBL16863561 | 0.99 | ABCC9 (0.42) | ABCC9KDM4E | |
| Sulfuric Acid SCHEMBL16027584 | 0.93 | ABCC9 (0.41) | ABCC9KDM4E | |
| SCHEMBL27535324 | 0.87 | ABCC9 (0.36) | ABCC9KDM4E | |
| SCHEMBL9200557 | 0.81 | CA12 (0.43) | ABCC9KDM4E | |
| SCHEMBL9200569 | 0.81 | CA12 (0.43) | ABCC9KDM4E | |
| SCHEMBL9200576 | 0.81 | CA12 (0.43) | ABCC9KDM4E | |
| SCHEMBL15257366 | 0.80 | KDM4E (0.41) | ABCC9KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20160318892-A1 | PRODRUG COMPOUNDS | PROXIMAGEN LIMITED (GB) | 2016-11-03 | — | — | US | disclosed |
| US-20160318892-A1 | PRODRUG COMPOUNDS | PROXIMAGEN LIMITED (GB) | 2016-11-03 | — | — | US | disclosed |
| WO-2015097461-A1 | PRODRUG COMPOUNDS | PROXIMAGEN LIMITED (GB) | 2015-07-02 | — | — | WO | disclosed |
| EP-1091950-B1 | SUBSTITUTED BENZOPYRAN DERIVATIVES AND THEIR USE AS ANTICONVULSANTS | SMITHKLINE BEECHAM PLC (GB) | 2003-04-09 | — | — | EP | disclosed |
| EP-0764158-B1 | BENZOPYRANS AND THEIR USE AS THERAPEUTIC AGENTS | SMITHKLINE BEECHAM PLC (GB) | 2002-09-18 | — | — | EP | disclosed |
| US-6395909-B1 | DRUGS FOR ANTICONVULSANTS | SMITHKLINE BEECHAM P.L.C. (GB) | 2002-05-28 | — | — | US | disclosed |
| EP-0764157-B1 | BENZOPYRANS AND THEIR USE AS THERAPEUTIC AGENTS | SMITHKLINE BEECHAM PLC (GB) | 2002-01-02 | — | — | EP | disclosed |
| EP-1114821-A1 | Benzopyrans and their use as therapeutic agents | SMITHKLINE BEECHAM PLC (GB) | 2001-07-11 | — | — | EP | disclosed |
| EP-1091950-A1 | SUBSTITUTED BENZOPYRAN DERIVATIVES AND THEIR USE AS ANTICONVULSANTS | SMITHKLINE BEECHAM PLC (GB) | 2001-04-18 | — | — | EP | disclosed |
| US-6211211-B1 | ANXIOLYTIC, ANTICONVULSANT AND ANTIEPILEPTIC AGENT | SMITHKLINE BEECHAM P.L.C. (GB) | 2001-04-03 | — | — | US | disclosed |
| WO-2000000484-A1 | SUBSTITUTED BENZOPYRAN DERIVATIVES AND THEIR USE AS ANTICONVULSANTS | SMITHKLINE BEECHAM PLC (GB) | 2000-01-06 | — | — | WO | disclosed |
| US-5760074-A | Treatment | SMITHKLINE BEECHAM P.L.C. (GB) | 1998-06-02 | — | — | US | disclosed |
| WO-1995034546-A1 | BENZOPYRANS AND THEIR USE AS THERAPEUTIC AGENTS | SMITHKLINE BEECHAM P.L.C. (GB) | 1995-12-21 | — | — | WO | disclosed |
| EP-0389861-B1 | Benzopyran derivatives and processes for preparation thereof | FUJISAWA PHARMACEUTICAL CO (JP) | 1995-08-23 | — | — | EP | disclosed |
| EP-0126367-B1 | Chroman and chromene derivatives | BEECHAM GROUP PLC (GB) | 1994-10-12 | — | — | EP | disclosed |
| US-5232938-A | For treatment of respiratory tract disorders, hypertension and urinary tract disorders | BEECHAM GROUP P.L.C. (GB) | 1993-08-03 | — | — | US | disclosed |
| US-5104890-A | Potassium channel activtors; vasodilators | FUJISAWA PHARMACEUTICAL COMPANY, LTD. (JP) | 1992-04-14 | — | — | US | disclosed |
| EP-0389861-A1 | Benzopyran derivatives and processes for preparation thereof | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1990-10-03 | — | — | EP | disclosed |
| US-4575511-A | Anti-hypertensive chromanol derivatives | BEECHAM GROUP P.L.C. (GB) | 1986-03-11 | — | — | US | disclosed |
| EP-0126367-A1 | Chroman and chromene derivatives | BEECHAM GROUP PLC (GB) | 1984-11-28 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160318892-A1 | PRODRUG COMPOUNDS | SCN1B, CACNA1E, SCN2B | ABCC9 370/4885KDM4E 2964/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.